Working out of sites in Korea and the U.S., D&D serves as the parent company for three spinouts from Johns Hopkins School of Medicine. The highest profile of the three subsidiaries is Neuraly, which raised a $36 million series A round last year to take long-acting glucagon-like peptide-1 receptor agonist NLY01 into the clinic.Read more >>
The Maryland biotech startup is developing new treatments for Parkinson’s disease and Alzheimer’s disease. Read more >>
Startup Neuraly Raises $36M to Bring Potential Disease-Modifying Treatments to Patients with Parkinson’s DiseaseZiad
Today, Neuraly announced its launch to pioneer the development of disease-modifying agents for neurodegenerative disorders. Read more >>
Boston Harbor Angels has invested in two neuroscience startups targeting stroke, TBI and Parkinson’s Disease, leading a $1.3M angel seed round in Astrocyte Pharmaceuticals and members investing in Neuraly.
Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke, TBI, concussion, and neurodegenerative disorders […]